CREO MEDICAL GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.75 GBX | -2.05% |
|
+10.00% | -22.28% |
| May. 15 | Creo Medical on track to break even next year on strong 2023 results | AN |
| May. 15 | Creo Medical Group PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's enterprise value to sales, at 3.28 times its current sales, is high.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -22.28% | 162M | - | ||
| +75.35% | 12.38B | B- | ||
| -20.50% | 7.76B | C+ | ||
| +7.83% | 6.61B | C- | ||
| +12.49% | 5.4B | D+ | ||
| +37.02% | 4.96B | - | ||
| -17.23% | 4.75B | B | ||
| -24.72% | 3.89B | B- | ||
| -27.83% | 2.66B | C | ||
| +56.93% | 2.45B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CREO Stock
- Ratings Creo Medical Group PLC